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Background: Adjuvant chemotherapy for stage III colon cancer is internationally accepted as standard treatment
with established efficacy, but the usefulness of adjuvant chemotherapy for stage II colon cancer remains
controversial. The major Western guidelines recommend adjuvant chemotherapy for “high-risk stage II” cancer, but
this is not clearly defined and the efficacy has not been confirmed.
Methods/design: SACURA trial is a multicenter randomized phase III study which aims to evaluate the superiority
of 1-year adjuvant treatment with UFT to observation without any adjuvant treatment after surgery for stage II
colon cancer in a large population, and to identify “high-risk factors of recurrence/death” in stage II colon cancer
and predictors of efficacy and adverse events of the chemotherapy. Patients aged between 20 and 80 years with
curatively resected stage II colon cancer are randomly assigned to a observation group or UFT adjuvant therapy
group (UFT at 500–600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by 2-day rest. This
1-week treatment cycle is repeated for 1 year). The patients are followed up for 5 years until recurrence or death.
Treatment delivery and adverse events are entered into a web-based case report form system every 3 months. The
target sample size is 2,000 patients. The primary endpoint is disease-free survival, and the secondary endpoints are
overall survival, recurrence-free survival, and incidence and severity of adverse events. In an additional translational
study, the mRNA expression of 5-FU-related enzymes, microsatellite instability and chromosomal instability, and
histopathological factors including tumor budding are assessed to evaluate correlation with recurrences, survivals
and adverse events.
Discussion: A total of 2,024 patients were enrolled from October 2006 to July 2010. The results of this study will
provide important information that help to improve the therapeutic strategy for stage II colon cancer.
Trial registration: ClinicalTrials.gov NCT00392899.
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In Japan, colorectal cancer is the second most common
cancer following stomach cancer, and the third most
fatal cancer following lung cancer and stomach cancer
[1]. Postoperative adjuvant chemotherapy has been
demonstrated to improve the outcome in stage III colon
cancer and is internationally accepted as standard treat-
ment. On the other hand, no consensus has been
reached on the usefulness of adjuvant chemotherapy for
stage II colon cancer.
A meta-analysis using the studies C-01 to C-04 of the
National Surgical Adjuvant Breast & Bowel Project
(NSABP) [2] showed that adjuvant chemotherapy signifi-
cantly decreased the risk of recurrence/death in both
Dukes’ B and C. However, other pooled analysis or large
population database review revealed no statistically sig-
nificant additive survival benefit of adjuvant therapy in-
cluding 5-FU+ leucovorin exclusively in stage II colon
cancer [3,4].
In Japan, Sakamoto et al. [5] reported the results of
the meta-analysis that adjuvant therapy with oral 5-FU
drugs (without concomitant use of leucovorin) contribu-
ted to significant improvement in recurrence-free sur-
vival (RFS) and overall survival (OS) in stage II colon
cancer. UFT (Taiho Pharmaceutical Co., Ltd., Tokyo,
Japan) is one of the most widely used oral 5-FU agent as
adjuvant chemotherapy for colorectal cancer in Japan.
UFT is a combination drug of tegafur and uracil at a
molar ratio of 1:4 and is characterized by long mainten-
ance of a high 5-FU concentration level converted from
tegafur in blood/tumors due to inhibition of degener-
ation of 5-FU by uracil. In the randomized controlled
trial (RCT) comparing 2-year adjuvant therapy using
UFT (400 mg/body) with observation without adjuvant
therapy in 289 patients after surgery for stage II/III
colon and rectal cancer [6], the 5-year RFS was signifi-
cantly better in the UFT group. However, the analysis
exclusively for colon cancer (160 patients) revealed no
significant difference (77.4% in the UFT group, 74.0% in
the observation group, p = 0.71). In the RCT comparing
1-year adjuvant therapy using UFT (400 mg/m2/day)
with observation without adjuvant therapy in 610
patients after surgery for stage III colon and rectal can-
cer [7], 1-year treatment with UFT was well tolerated
and significantly improved the RFS and OS in rectal can-
cer, while the analysis for 332 patients with colon cancer
showed no significant difference in both the 5-year RFS
(71.3% in the UFT group, 69.6% in the observation
group, p = 0.56) and OS.
Although both of the abovementioned two RCTs
[6,7] failed to demonstrate an additive effect, 1- or 2-
year postoperative adjuvant therapy with UFT alone
has often been used for stage II colon cancer in clin-
ical practice in Japan, because of its good feasibility [8]and low-cost. The Japanese Study Group for Post-
operative Follow-up of Colorectal Cancer reported that
the 5-year survival rate of 1,262 patients with stage II
colon cancer who underwent surgery between 1977
and 2000 was 82.1% [9]. Given such a good outcome,
it is necessary to clarify in a larger population whether
postoperative adjuvant treatment with UFT alone has
an additive effect on stage II colon cancer compared
with observation only.
On the other hand, the reports using a large-scale
database disclosed that stage II colon cancer included
subpopulations with different prognosis [9,10]. The
major Western guidelines recommended to select the
“high-risk group of recurrence” in stage II colon can-
cer and to give postoperative adjuvant chemotherapy.
The NCCN guidelines of 2012 [11] lists T4 lesions,
number of lymph-nodes examined <12, perforation,
lymphovascular involvement, poorly differentiated
histopathology, and perineural invasion as high-risk
factors, while the ASCO guidelines of 2004 [12] lists
inadequately sampled nodes, T4 lesions, perforation,
and poorly differentiated histology as factors for con-
sidering for adjuvant chemotherapy in stage II colon
cancer. In addition to these, high CEA is listed as
high-risk factor in the ESMO guidelines [13]. Recently,
the biomarker studies have proposed new risk factors
for recurrence/prognosis.
It seems appropriate to use adjuvant chemotherapy
for a subgroup with poor prognosis in stage II colon
cancer. However, the definition of “high-risk stage II”
is not clear yet, and the efficacy of adjuvant chemo-
therapy for those patients has not been demonstrated.
We therefore conducted the SACURA trial (Surgical
Adjuvant Chemotherapy with UFT for Curatively
Resected Stage II Colon Cancer), a multicenter phase
III RCT to verify the efficacy of adjuvant chemother-
apy for curatively resected stage II colon cancer in a
large population through evaluating the superiority of
1-year adjuvant treatment with UFT to observation
without any adjuvant treatment, and to identify “high-
risk factors of recurrence” in stage II colon cancer and
predictors of efficacy and adverse events (AEs) of the
chemotherapy.
Methods/design
The design of study
This study is a multicenter randomized phase III trial, in
which patients with curatively resected stage II colon
cancer are randomly assigned to either the observation
group or UFT adjuvant therapy group (Figure 1). The
primary endpoint is disease-free survival (DFS), and the
secondary endpoints are OS, RFS, and incidence and se-
verity of AEs. Superiority of adjuvant therapy with UFT
compared to observation without any adjuvant therapy
Eligibility criteria
1) Pathologycally comfirmed colon 
adenocarcinoma
2) Pathologically comfirmed stage II 
3) Curatively resected
4) Aged 20-80 years at registration
5) ECOG performance status (PS) of 0 to 1
6) No prior chemotherapy or radiotherapy 
for colon cancer
7) Able to take medications orally
8) Adequate organ functions
9) Able to start the protocol treatment within 
8 weeks after surgery




Adjuvant therapy with UFT
500-600mg as tegafur in 2 devided doses
Days 1-5 followed by a 2-day rest
Repeating  for 1 year
Stratification factors
Depth of tumor invasion (T3 vs. T4)



















Figure 1 Study schema.
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surgical specimens are collected for histopathological
and biomolecular assessments.
Enrollment and allocation
Eligible patients are enrolled at the Translational Re-
search Informatics Center using a web-based system.
Patients are randomly assigned, in a 1:1 ratio, to either
an observation group or UFT adjuvant therapy group,
using minimization by introducing a random element
with a 0.8 assignment probability [14], balanced on the
following stratification factors: depth of tumor invasion
(T3 vs. T4), number of lymph-nodes examined (<12 vs.
≥12) and institution (Figure 1). Treatment assignment is
not masked from the investigators and patients.
The main eligibility criteria are as follows:
Inclusion criteria
1) Histologically confirmed stage II colon cancer
2) Histologically confirmed adenocarcinoma
3) Has undergone curative surgery
4) Age: 20–80 years
5) ECOG performance status: 0–1
6) No prior chemotherapy or radiotherapy for colon
cancer
7) Able to take medications orally
8) Adequate organ functions as listed below
(at ≤14 days prior to enrollment)
i) Leukocytes: 3,500/mm3 to 12,000/mm3
ii) Neutrophil: ≥ 1,500/mm3
iii)Hemoglobin ≥ 9.0 g/dL
iv) Platelet count ≥ 100,000/mm³
v) Total bilirubin ≤ 2.0 mg/dL
vi)Aspartate aminotransferase (AST), alanine
aminotransferase (ALT): ≤ 100 IU/L
vii) Creatinine: ≤1.5 mg/dL9) Able to start the protocol treatment within 8 weeks
after surgery
10)Has provided written informed consent
Exclusion criteria
1) Other active malignancies (i.e. diagnosed within
5 years) (Tis colorectal cancers are allowed to
enroll)
2) Hereditary colorectal cancer
3) Severe comorbidities:
i) Severe postoperative complication
ii) Uncontrollable diabetes mellitus
iii)Uncontrollable hypertension
iv)Myocardial infarction within 6 months
v) Unstable angina pectoris
vi) Cirrhosis or liver failure
vii) Interstitial pneumonia, pulmonary fibrosis, or severe
emphysema
viii)Psychiatric disorder
4) Concern about pregnancy
5) The investigator considers the patient not suitable
for the study
Protocol treatment
Assigned treatment is started within 8 weeks after
surgery.
Observation group
Patients are followed-up without adjuvant treatment,
according to the schedule defined in the study protocol
for 5 years until recurrence, other malignancy or death
is confirmed (Figure 2).
UFT adjuvant therapy group
UFT is given at a dose of 500–600 mg/day as tegafur in
2 divided doses after meals for 5 days, followed by a
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year. During protocol treatment, clinical findings and
laboratory values are evaluated every month.
Protocol treatment is started and continued when
the patients fulfill the following criteria: leukocytes
≥3,000/mm3, platelets ≥100,000/mm3, AST and ALT
≤100 IU/L, total bilirubin ≤2.0 mg/dL, no greater than
grade 2 anorexia, nausea, vomiting, or diarrhea. If the
criteria for starting/continuing treatment are not met,
treatment is postponed or temporarily suspended
until AEs improve to meet the criteria. And then,
treatment is resumed at one dose level lower
(−200 mg). The dose can be reduced if the physician
judges that dose reduction is necessary. Once the dose
has been reduced, it is not to be subsequently re-
increased.
Protocol treatment is discontinued in the cases as
follows: treatment fails to be resumed within 29 days
after being postponed or temporarily suspended (the
planned drug rest is not included), the physician
judges that the protocol treatment is difficult to con-
tinue due to AEs, recurrence or other malignancies
develop, the patient requests discontinuation of proto-
col treatment, and the patients withdraw informed
consent.
After the completion of protocol treatment, patients
are followed-up following the same schedule as for the
observation group (Figure 2) until recurrence, other ma-
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Figure 2 Observation, examination, and report schedule.Evaluation of treatment delivery and adverse events
Treatment delivery (UFT adjuvant therapy group only)
Physicians report the treatment delivery via a web-based
case report system, including the followings: daily dose,
drug compliance*, temporary suspension (+/-), number
of days of suspension, reason for suspension, dose re-
duction (+/-), etc.
* The drug compliance for each 3 months period is
defined as the ratio of the dose actually taken to the pre-
scribed dose, and is classified to the following 4 categories:
1) ≥90% taken, 2) ≥75% to <90% taken, 3) ≥50% to <75%
taken, and 4) <50% taken.
Safety profile (both groups)
The types and severities of AEs from the start of protocol
treatment to 30 days after the last administration are eval-
uated according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 3.0.
The most severe grade of each AE is reported every
3 months. The following AEs are required to be reported
as “priority survey items”: leukocytes, hemoglobin, plate-
lets, total bilirubin, AST, ALT, stomatitis, anorexia, nausea,




The primary endpoint of this study is DFS, and the sec-
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http://www.biomedcentral.com/1471-2407/12/281severity of AEs. DFS is defined as the time to recurrence,
other malignancies or death, whichever comes first.
Patients alive and free of recurrence or other malignan-
cies are censored at time of last follow-up. RFS is defined
as the time to recurrence or death. Patients alive and free
of recurrence are censored at time of last follow-up. The
intervals are calculated from the date of enrollment.Definition of target sample size
In two clinical studies conducted in Japanese patients
with colon cancer in the 1990’s, the 5-year DFS rate in
patients without adjuvant chemotherapy was 74.3%
(Dukes’ B) [15] and 74.0% (Dukes’ B and C) [6]. Given a
recent improved surgical outcome, it was assumed that
the 5-year DFS rate would be 80% in the control group
(observation group). With an expected 5-year DFS rate
of 85% (hazard ratio: 0.729) in the study treatment group
(UFT adjuvant therapy group), a two-sided significance
level of 5%, and a power of 90%, the necessary sample
size was calculated to be 970 patients per group accord-
ing to the method described by Shoenfeld et al. [16]. A
target sample size of 1,000 patients per group (a total of
2,000 patients in two groups) was determined in consid-
eration of a 3% excluded rate.Analysis plan
The primary analyses are done on an intent-to-treat
basis. The survival curves (DFS, OS, and RFS) are esti-
mated by the Kaplan-Meier method, and the stratified
log-rank test, stratified by the depth of tumor invasion
and the number of lymph-nodes examined, are used to
test the null hypothesis that the respective curves are
equal between the two groups. The hazard ratio is1) Analysis of mRNA expression of enzymes rel
metabolism, and tumor progression 
- TS (thymidylate synthase)
- DPD (dihydropyrimidine dehydrogena
- TP (thymidine phosphorylase)
- OPRT (otate phosphoribosyl transferas
- FPGS (folylpolyglutamate synthetase)
- VEGF (vascular endothelial growth fac
- COX-2 (cyclooxygenase-2)
2) Analysis of microsatellite instability (MSI) an
3) Evaluation of histopathological factors in HE-
- tumor budding
- extent of the poorly differentiated comp
- Crohn’s-like lymphoid reaction
- fibrotic cancer stroma etc.
Figure 3 Items included in additional translational study.estimated using a stratified proportional hazard model.
A two-sided significance level of 5% is used. Subgroup
analyses are performed according to sex, age, depth of
tumor invasion, and number of lymph-nodes examined
for comparison between the two groups.
The treatment delivery in the UFT adjuvant therapy
group is summarized. The incidence of AEs between
two groups is compared with the Fisher’s exact test.
An interim analysis of the efficacy is planned at 3 years
after enrollment of the last patient. For the primary end-
point (DFS), the significant levels in interim and final
analyses are determined according to α spending func-
tion (the O’Brien-Fleming type) to keep the overall type
I error at 5%.
Additional translational study
The assessments shown in Figure 3 are made in paraffin-
embedded thin sections of surgical specimens from pri-
mary tumors to evaluate the correlation with recurrences,
survivals and AEs. The details of methods and analytical
procedures will be reported separately.
Ethical matters
This study is conducted in accordance with the “Declar-
ation of Helsinki” and “Ethical Guidelines for Clinical Re-
search,” and has been approved by the Institutional Review
Boards of each participating institute. Written informed
consent is obtained from all patients before enrollment.
Discussion
This study is conducted to prospectively evaluate adju-
vant chemotherapy for stage II colon cancer in terms of




d chromosomal instability (i.e., 18qLOH) 
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http://www.biomedcentral.com/1471-2407/12/281According to the Japanese “Guidelines for the Treat-
ment of Colorectal Cancer” [17] published by the Japa-
nese Society for Cancer of the Colon and Rectum
(JSCCR), adjuvant chemotherapy is recommended for
stage III colorectal cancer. However, in line with the
major Western guidelines [11-13], the JSCCR guide-
lines states that adjuvant chemotherapy for stage II
colon cancer is considered for patients with a “high-
risk factor of recurrence” after adequate informed con-
sent, although the efficacy of adjuvant chemotherapy
for stage II colon cancer is not clearly demonstrated
and “high-risk stage II” is not clearly defined. No def-
inite conclusion has been reached on this clinically im-
portant issue, probably for the following reasons: 1)
large number of patients would be required to evaluate
the efficacy of adjuvant chemotherapy for stage II
colon cancer because of good surgical outcome; and 2)
no high-quality RCT for stage II colon cancer alone
has been conducted.
The SACURA trial is a RCT in patients with curatively
resected stage II colon cancer, evaluating whether 1-year
adjuvant treatment with UFT improves the DFS and OS
compared with observation without adjuvant treatment
(superiority study). Between October 2006 and July
2010, a total of 2,024 patients were enrolled from the
270 institutes. In Japan, complete mesocolic excision
with central vascular ligation (D3 dissection) [17-19] is
the standard surgery for colon cancer. The institutions
which met the conditions that the member of the
JSCCR, more than 80 colorectal cancer surgery each
year and D3 dissection as routine surgery were selected
for the study to insure the quality of the study.
In the present study, the observation group is used to
investigate the clinicopathological high-risk factors for
recurrence, and the UFT adjuvant therapy group is used
to evaluate the effect of adjuvant therapy on the
patients with those “high-risk factors”. These assess-
ments will provide useful information to determine the
indication of adjuvant therapy for patients with stage II
colon cancer.
New reliable risk factors of recurrence other than rou-
tine items in histopathological examination are expected.
The present study evaluates the following histopatho-
logical markers as promising prognostic factors for stage
II colorectal cancer: tumor budding [20], extent of the
poorly differentiated component [21], Crohn’s-like
lymphoid reaction [22], and fibrotic cancer stroma [23].
This is the first study to evaluate those new possible
prognostic histopathological markers prospectively using
a large sample size.
In recent years, risk classification for recurrence/prog-
nosis and prediction of efficacy to chemotherapy based
on the biomolecular profiles are intensively studied. The
meta-analysis reported that MSI-high stage II colorectalcancer was characterized by a lower recurrence rate and
better prognosis, compared with MSI-low and
microsatellite-stable stage II colorectal cancer [24]. On
the other hand, the pooled analysis disclosed that adju-
vant chemotherapy with 5-FU drugs for MSI-high colo-
rectal cancer resulted in poorer OS than those of patients
without the chemotherapy [25], indicating that MSI may
be interesting as a predictor of efficacy to 5-FU based
chemotherapy. Deletion or loss of heterozygosity (LOH)
of the long arm of chromosome 18 (18q) is considered as
an indicator of chromosomal instability [26,27], which
can be related to carcinogenesis and tumor progression.
In the PETACC-3 molecular study [28], both the univari-
ate and multivariate analyses in 420 patients without ad-
juvant chemotherapy after surgery for stage II colon
cancer revealed that 18qLOH was a significant factor for
poor prognosis and that MSI-high was a significant fac-
tor for good prognosis. In the present study, MSI and
18qLOH are evaluated in more patients collected pro-
spectively than those in the PETACC-3 study.
The efficacy and AEs of 5-FU drugs may be related to
5-FU-related enzymes in blood or tumor [29,30]. In
Japan, several oral 5-FU drugs with differing mechan-
isms of action have been frequently used, but few pro-
spective studies with a large sample size about this issue
have been conducted. In the present study, the tumor
mRNA expression levels of enzymes related to nucleic
acid metabolism, folic acid metabolism, and tumor pro-
gression are measured to evaluate the correlation with
the prognosis and AEs to identify predictors of efficacy
and safety. In the future, it is expected that oral 5-FU
drugs can be used in personalized ways based on differ-
ences in the appearance of these enzymes.
In conclusion, the SACURA trial is a large, multicenter
phase III RCT intended to demonstrate the efficacy and
safety of postoperative adjuvant therapy in patients with
stage II colon cancer by showing the superiority of 1-year
adjuvant treatment with UFT to observation without any
adjuvant treatment. The results will identify 1) “high-risk
stage II” colon cancer, 2) predictors of efficacy and AEs
of adjuvant chemotherapy with 5-FU drugs and 3) sub-
group benefited from adjuvant chemotherapy, and will
contribute to establish an improved therapeutic strategy
for stage II colon cancer.
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